Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
Thierry Dervieux¹, Joel Kremer ², Kelley Brady ¹, Chihiro Takahashi ³, Tsutomu Takeuchi ⁴ and Yuko Kaneko ⁵, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Keio University Hospital Division of Rheumatology, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
Abstract Number: 508 • 2019 ACR/ARP Annual Meeting
Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Sakae Tanaka ³, Atsushi Kawakami ⁴, Yeong-Wook Song ⁵, Yi-Hsing Chen ⁶, Mitsuhiro Rokuda ⁷, Hiroyuki Izutsu ⁷, Satoshi Ushijima ⁷, Yuichiro Kaneko ⁷, Yoshihiro Nakashima ⁷, Teruaki Shiomi ⁷ and Emi Yamada ⁷, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Seoul National University Hospital, Seoul, Republic of Korea, ⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁷Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…
Abstract Number: 547 • 2019 ACR/ARP Annual Meeting
Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis
Charles Peterfy¹, Mark Genovese ², In-Ho Song ³, Alan Friedman ⁴, Stephen Hall ⁵, Eduardo Mysler ⁶, Patrick Durez ⁷, Xenofon Baraliakos ⁸, Jose Jeffrey Enejosa ⁹, Tim Shaw ⁴, Yihan Li ⁹, Su Chen ⁴ and Vibeke Strand ¹⁰, ¹Spire Sciences Inc, Boca Raton, ²Stanford University, Stanford, CA, ³AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁴AbbVie Inc., North Chicago, ⁵Monash University and Emeritus Research, Melbourne, Australia, ⁶Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁷Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁸Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Long‑term prevention of structural joint damage is a key treatment goal in the management of RA1. Upadacitinib (UPA), a JAK1-selective inhibitor, inhibited the progression…
Abstract Number: 995 • 2019 ACR/ARP Annual Meeting
Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts
Wan-Hee Yoo¹, Yunjung Choi ², Eun-gyeong Lee ², Chang-hoon Lee ³ and Myeung-Su Lee ³, ¹Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical, Research Institute of Chonbuk National University Hospital, Jeonju, Korea, JeonJu, Republic of Korea, ²Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, JeonJu, Republic of Korea, ³Wonkwang University College of Medicine, Iksan, Republic of Korea
Background/Purpose: Several studies have recently revealed the pathological role of endoplasmic reticulum (ER) stress in the pathogenesis of inflammatory diseases. In addition, 4-phenylbutyric acid (4-PBA) was…
Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Joe Zhuo ⁷, Kuan-Hsiang Gary Huang ⁸, Robert Wong ⁷, Sean Connolly ⁸, Yedid Elbez ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Excelya, Boulogne-Billancourt, France, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…
Abstract Number: 2016 • 2019 ACR/ARP Annual Meeting
Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis
Masayoshi Harigai¹, Ryoko Sakai ², Takahiko Sugihara ³ and Akihito Ishigami ⁴, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Tokyo Medical and Dental University, Tokyo, Japan, ⁴Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
Background/Purpose: Peptidyl-arginine deiminases (PADIs) are enriched in neutrophils and considered to be responsible for citrullination of proteins in vivo. Autoantibody against citrullinated proteins are frequently…
Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³ and Daisuke Kato ³, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
Abstract Number: 510 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels
Christina Charles-Schoeman¹, Thierry Sornasse ² and Jeremy Sokolove ², ¹University of California, Los Angeles, CA, ²AbbVie Immunology Clinical Development, Redwood City
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory condition associated with increased rates of atherosclerotic progression via pathogenic remodeling of high-density lipoprotein (HDL)-associated proteins, resulting…
Abstract Number: 550 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Rene Westhovens ², Kevin Winthrop ³, Susan Lee ⁴, Joy Greer ⁴, Adam DeZure ⁴, Di An ⁴, Lei Ye ⁴, John Sundy ⁴, Robin Besuyen ⁵, Luc Meuleners ⁵, Rieke Alten ⁶ and Mark Genovese ⁷, ¹University of California, San Diego School of Medicine, La Jolla, CA, ²University Hospitals, Leuven, Belgium, ³Oregon Health and Science University, Portland, OR, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Schlosspark-Klinik University Medicine, Berlin, Germany, ⁷Stanford University, Stanford, CA
Background/Purpose: Filgotinib (FIL) is an oral selective Janus kinase (JAK1) inhibitor. In studies to date, FIL has been shown to be effective and safe in…
Abstract Number: 996 • 2019 ACR/ARP Annual Meeting
The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages
Qi Huang¹, Renee Doyle ¹, Shang-Yang Chen ², Alexander Misharin ³, Deborah Winter ⁴ and Richard Pope ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Feinberg School of Medicine, chicago, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, ⁵Northwestern University Feinberg School of Medicine, Division of Rheumatology, chicago, IL
Background/Purpose: We previously identified that under homeostatic conditions Flip was necessary for macrophage (MΦ) survival. The mechanisms responsible for the differentiation of monocyte-derived MΦs into…
Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting
Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis
Omar Valenzuela ¹, Sebastian Ibanez², Maria Paz Poblete ³, Claudia Mardones ², Francisco Silva ², Maria Jose Villar ² and Katherine Mogollones ¹, ¹Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile, ²Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ³Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…
Abstract Number: 2126 • 2019 ACR/ARP Annual Meeting
Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis
Yan Qin¹, Xiangcong Zhao ¹ and Jing Luo ¹, ¹the Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic)
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer a high susceptibility to infection, and many inflammatory cytokines are prognostic in RA, but currently the role of cytokines in identifying infection individuals…
Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting
Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Thierry Dervieux¹, Kelley Brady ¹, Don Thomas ², John Conklin ¹, Eugene Fung ³, Claudia Ibarra ¹ and Michelle Petri ⁴, ¹Exagen, Vista, CA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Arthritis & Osteoporosis Clinic, Waco, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…
Abstract Number: 511 • 2019 ACR/ARP Annual Meeting
A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
Maya H. Buch¹, Alvin F. Wells ², Andrea Rubbert-Roth ³, Manish Jain ⁴, Casey Schlacher ⁵, Heidi Camp ⁵, Yihan Li ⁵, Yanna Song ⁶ and Peter Nash ⁷, ¹University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Rheumatology and Immunotherapy Center, Franklin, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has demonstrated efficacy and safety in patients with rheumatoid arthritis (RA) as monotherapy and in combination with conventional…
Abstract Number: 816 • 2019 ACR/ARP Annual Meeting
The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts
Muriel Elhai¹, Raphael Micheroli ¹, Mojca Frank-Bertoncelj ², Kerstin Klein ¹, Oliver Distler ³ and Caroline Ospelt ², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland., Zürich, Switzerland, ²University Hospital Zürich, Zürich, Switzerland, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Mechanisms involved in joint patterning of rheumatic diseases remain unknown. The long non-coding RNA HOTAIR is exclusively expressed in synovial fibroblasts (SF) from lower…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].